About this event
Dr. Claudio Iovino (MD, PhD) shares two major case reports from LightWave I, our multi-centric clinical trial focused on the application of LM® LLLT (PBM) technology in the management of AREDS 2 & 3 dry Age-related Macular Degeneration (dAMD) with eye-light®.
The case reports, recently accepted for publication at ARVO 2024, present two impressive cases of patients with dry AMD and non-neovascuar AMD who benefitted from LM® LLLT therapy.
In the keynote Dr. Iovino will discuss:
- How dAMD will increasingly impact modern society
- How LM® LLLT photobiomodulation technology works, and the promise it holds
- LightWave I Clinical Trial: what it is, what we're doing, where we're going
- Case Report 1: AREDS 3 dry AMD
- Case Report 2: Non-neovascular AMD w/ PED and Subretinal Fluid
- LightWave II Clinical Trials: how to apply
The event will be followed by a LIVE Q&A session with Espansione's Medical Affairs Team.
Espansione Group
Science OnwardEspansione Group is a pioneering company in the field of photobiomodulation in ophthalmology and beyond.
